Status:
RECRUITING
Differential Effects of in Vivo and Virtual Exposure Therapy in Agoraphobia
Lead Sponsor:
Johannes Gutenberg University Mainz
Conditions:
Agoraphobia; Panic
Social Anxiety Disorder
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Anxiety disorders, including agoraphobia, are prevalent in the German population, leading affected individuals to avoid specific places like crowds or public transport. Although cognitive-behavioral t...
Detailed Description
Anxiety disorders are among the most common mental illnesses in the German population. Agoraphobia is an anxiety disorder characterized by the avoidance of specific places. Individuals affected by ago...
Eligibility Criteria
Inclusion
- Experimental group: Diagnosis of agoraphobia with or without panic disorder
- Clinical control group: diagnosis of social phobia
- Control group: healthy individuals without acute or chronic mental illness
- A depressive disorder may be present as a comorbid diagnosis in the experimental group and the clinical control group
Exclusion
- Other mental illnesses: Substance dependence, schizophrenia, bipolar disorder, dementia, eating disorders, PTSD, major depressive episode, personality disorder
- Somatic diseases: Cancer, cardiovascular diseases, epilepsy, autoimmune diseases, metabolic or endocrine diseases
- Taking psychotropic medication (except antidepressants) or medication that affects the cardiovascular system (e.g. beta-blockers), medication containing cortisone, use of creams with corticosteroids
- Pregnancy, breastfeeding
- Ongoing psychotherapy
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT06514495
Start Date
May 1 2025
End Date
August 1 2027
Last Update
September 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center
Mainz, Germany, 55122